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Nitrite inhalants are commonly abused
substances in the United States, primarily
by homosexual men and others who use
nitrites to facilitate sexual intercourse
and/or produce euphoria (1-4). Scientific
interest in nitrites increased in the 1980s
due to their possible links to AIDS (5-11).
In this paper we review the history, appli-
cations, and prevalence of use of nitrite
inhalants. We present the hypotheses link-
ing their use to AIDS. We provide sugges-
tions to physicians, community leaders,
policymakers, and researchers on what they
can do to limit the use ofnitrites.
History and Clinical Uses
The alkyl nitrites (e.g., amyl, butyl, iso-
propyl) are colorless or yellow liquids at
room temperature and are highly volatile.
They are esters of nitrous acid that have a
fruity odor (often described as unpleasant)
and have been nicknamed "poppers" because
ofthe sound made when glass capsules con-
taining amyl nitrite are crushed (12).
The vasodilatory effect following
inhalation of amyl nitrite vapor was
described in 1859 and led to the first
report of its clinical application to provide
relief for angina pectoris in 1867 (13,14).
In the 1880s, butyl nitrites were found to
have similar vasodilatory qualities, but
these compounds were never developed for
clinical use (12).
Amyl nitrite was initially marketed as a
prescription drug in the United States in
1937 and remained a prescription drug
until September 1960, when the Food and
Drug Administration (FDA) eliminated
the prescription requirement. In the 1960s,
nitroglycerin sublingual tablets, dermally
applied ointments, and, later, transdermal
patches began to replace amyl nitrite as the
preferred treatment for angina pectoris. In
the late 1960s, pharmacists and drug man-
ufacturers noticed widespread purchases of
amyl nitrite by apparently healthy young
men. These over-the-counter purchases
became the impetus for the FDA to rein-
state the prescription requirement in 1968.
Since then an underground market for
amyl nitrite has emerged (15). For the last
few years, there has been no medical adver-
tising for pharmaceutical-grade amyl nitrite,
and it is no longer listed in the Physician's
DeskReference (16).
Amyl nitrite remains available by pre-
scription. The clinical indication listed in
the package insert is angina pectoris (17).
Amyl nitrite is used experimentally to treat
cyanide poisoning. The drug produces
methemoglobin, which has a high affinity
for cyanide, and leads to the production of
cyanomethemoglobin, releasing cyanide
from cell mitochondrial cytochrome oxidase
sites, where it is otherwise destructive (18).
When amyl nitrite became difficult to
procure for nonmedical or recreational pur-
poses during the 1970s, there was a prolif-
eration of butyl nitrite products by non-
pharmaceutical manufacturers (15). Butyl
nitrites were marketed as "liquid incense"
or "room odorizers." Because the labels on
bottles containing butyl nitrites stated that
they were not to be inhaled and no health
claim was made, the FDA never had juris-
diction over this product as it does medi-
cine and many foods.
The legal status of some key nitrite
preparations has changed in the past few
years. One development prompting this
change has been the description of several
acute and chronic adverse effects attributed
to the abuse of nitrite inhalants (15). In
response to those reports, the U.S.
Congress enacted a ban on the manufac-
ture and retail sale ofbutyl nitrites (except
when used in specified chemical commer-
cial processes) in the Anti-Drug Abuse Act
of 1988 (Public Law 100-690, Section
2404). The law specified that the Con-
sumer Product Safety Commission (not the
FDA) would enforce the ban. However, to
circumvent the clear intent of the law,
nitrite manufacturers began to sell other
nitrite alkyl congeners, such as isopropyl
nitrite, as "new and improved" room odor-
izers. In 1990, Congress outlawed manu-
facture and sale of alkyl nitrites in the
Omnibus Crime Bill (Public Law 101-647,
Section 3202). Since then, at least one
manufacturer has developed a cyclohexyl
nitrite inhalant and marketed it diversely.
According to chemical nomenclature,
cyclohexyl nitrites are not in the same class
as alkyl nitrites and therefore may not be
banned under current federal law.
Underground manufacturers and importers
continue to market butyl and isopropyl
nitrites illegally.
The acute toxicity of inhaled and
ingested nitrites in humans includes skin
irritations (especially around the nose and
lips), tracheobronchial irritation, headache,
hypotension, cyanosis, methemoglobine-
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mia, intoxication, and, rarely, death (15).
Other effects include development of
habitual use patterns, tolerance, and burns
resulting from inadvertent ignition of the
vapor. The National Toxicology Program
ofthe National Institute ofEnvironmental
Health Sciences evaluated mice and rats
exposed short term (6 hr/day for 14 days
and 13 weeks) to inhaled isobutyl nitrite at
concentrations ranging from 0 to 800 ppm
and noted several adverse effects. Rats
exposed to greater than 600 ppm died dur-
ing the 14-day studies. At lower exposure
levels, the most striking lesion seen in mice
was hyperplasia of the nasal mucosa and
bronchial and bronchiolar tree.
Methemoglobinemia was confirmed.
Other adversely affected organs included
the liver, spleen, thymus, and bone mar-
row (19).
Prevalence ofNonmedical Nitrite Use
Alkyl nitrites are among the most com-
monly used inhalants in the United States.
Other commonly abused inhalants are
nitrous oxide, gasoline, glues, and solvents,
such as paint thinners. The National
Institute on Drug Abuse has collected
information concerning nitrite inhalant
use among high school seniors since 1979.
Eleven percent of high school seniors
interviewed in 1979 reported ever using
nitrites. Use has decreased consistently
among seniors since 1980, to 1.5% for the
class of1992 (20).
According to national surveys, self-
reported amyl and butyl nitrite use varies
by gender, region, and race. Male high
school seniors reported higher rates of
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inhalant use and nitrite use than females.
The proportion ofmales who used nitrites
at least once was typically twice the per-
centage of females reporting lifetime use
(20). The highest rate ofnitrite use report-
ed by high school seniors in 1979 was in
the Northeast, and the lowest rate was
reported in the West. Rates have decreased
markedly in all regions, with the highest
rates in 1992 reported in the North-
Central United States and the lowest rates
in the Northeast (21).
Nitrite use varies by race/ethnicity as
well as geographic area. Although
racial/ethnic data are not available for high
school seniors, the Public Health Service-
sponsored National Household Survey
provides limited population-based esti-
mates. Self-reported nitrite use in 1991 was
highest for white males in each of six
selected metropolitan areas for which data
were analyzable. National estimates of use
by females was 1.3% for white females in
1991, 0.7% for black females, and 0.8%
for Hispanic females (22).
Nitrite use has been commonly reported
among homosexual men for several
decades, but less so for self-identified het-
erosexual adolescents and adults. In 1981,
Centers for Disease Control and Pre-
vention (CDC) investigators surveyed 420
men attending sexually transmitted disease
clinics in New York, San Francisco, and
Atlanta and found that 242 of 279 (86%)
homosexual/bisexual men compared with
21 of 141 (15%) heterosexual men report-
ed any use of nitrite inhalants within the
previous 5 years (6). Almost all gay men
enrolled in an AIDS case-control study
conducted by CDC in 1981 reported use
of nitrites (23). Other studies of gay men
in the United States, Canada, and Europe
found high rates of nitrite use (24-29). A
multisite study demonstrated a marked
decrease of nitrite use among gay men
from 66% to about 35% between 1984
and 1989 (L. Jacobson, personal commu-
nication). Possible explanations for this
trend include increased awareness of
adverse effects, including concern about
nitrites' possible links to AIDS, and
decreased availability after nitrites were
banned as consumer products (30).
Hypotheses Linking Nitrites andAIDS
At least four separate hypotheses have been
proposed that suggest a role for nitrites in
the pathogenesis of AIDS. When AIDS
cases were first recognized in 1981, nitrites
were proposed as a possible cause of the
new syndrome (5,6). Nitrite abuse was
virtually universal among the gay men
diagnosed with AIDS in 1980-1983.
However, this hypothesis was dismissed
when the disease was recognized among
drug injectors, hemophiliacs, and other
heterosexual men and women who did not
consistently report using nitrites. In 1983
and 1984, human immunodeficiency virus
(HIV) was discovered and reported as the
cause of AIDS (31,32). Subsequently,
three other hypotheses suggesting nitrites
as promoting factors in AIDS have been
proposed. First, nitrites have been pro-
posed to enhance HIV transmission by
their association with risky sexual behaviors
and HIV infection among gay men.
Second, nitrite use has been associated
with immune suppression and thus might
hasten the onset of symptomatic disease.
Third, nitrite inhalant use has been associ-
ated with the development ofAIDS-related
Kaposi's sarcoma.
Nitrites and Sexual Behavior/HIV
Transmission. Several studies have linked
nitrite use with risky sexual behavior
and/or HIV infection among gay men.
Ostrow et al. found these associations in
the Multicenter AIDS Cohort Study
(29,30). A similar correlation was not
found for other substances of abuse,
including alcohol (30). Stall et al. (33)
linked nitrite, alcohol, marijuana, and
other drug use during sex with increased
likelihood of "risky" sexual behavior for
HIV infection among gay men in San
Francisco. They did not identify a unique
risk for nitrites independent of several
other drugs studied (33). In a longitudinal
study of 249 gay men in Toronto,
Calzavara et al. (28) found a significant
decline in sexual activities associated with
HIV infection and that nitrites and other
drug use during sex are strong predictors of
continuation of high-risk behaviors for
HIV infection. Among all the variables
tested, Penkower et al. (34) found that
nitrite inhalant use was the most strongly
associated with HIV seropositivity among
a cohort of 1045 gay men.
Nitrites and the Immune System. The
hypothesis that nitrite inhalants might
induce immune suppression was first
advanced by Goedert et al. in 1982 (8). T-
lymphocyte abnormalities were reported in 9
of 10 gay men who reported regular nitrite
use compared to 1 of 7 who did not use
nitrites (8). This study came under criticism
because of its small numbers and lack of
evaluation for many potentially confounding
variables, including HIVinfection.
Several other investigators have evaluat-
ed the effects of nitrites on human
immune function. Hersh et al. (35) cul-
tured venous blood with up to 1% isobutyl
nitrite in alcohol and, after 24 hr, observed
irreversible effects on various lymphocyte
functions, including blastogenesis, cell-
mediated cytotoxicity, and monocyte
adherence. Dax et al. (36) at the Addiction
Research Center studied the effects ofthree
inhalations at various concentrations per
day for 3 or 18 days on the immune sys-
tems of 18 male volunteers. One inhala-
tion of amyl nitrite (0.18, 0.36, or 0.48
ml) was administered from a closed 4-1
flask at 3-hr intervals each day of study.
After full exhalation, the subject inhaled
from the flask through the mouthpiece
with the nose "clipped" and held at full
inspiration for 5 sec before exhalation.
Blood was drawn for immune profile
immediately after the last inhalation and 1,
4, and 7 days later. Modest depression of
T-lymphocyte counts and natural killer cell
activity were noted with a rebound to at
least baseline levels several days after the
last inhalations. Cell proliferation respons-
es to phytohemagglutinin (PHA), con-
canavalin A (Con A), and pokeweed mito-
gen (PWM) were unaffected by amyl
nitrite inhalation (36).
Ross and Drew (37) interviewed 97 gay
men inAustralia and measured T-cell counts
and mitogenesis responses to PHA, Con A,
and PWM. T-lymphocyte counts did not
differ between nitrite users and nonusers.
Mitogenesis in response to the three antigens
was significantly higher in users compared
with nonusers after cells were incubated for
72 hr, but the differences disappeared for
PHAand ConAby 96 hr (37).
Studies of the immune system of mice
following nitrite challenge are even less
consistent than those among humans.
Studies evaluating nitrites' effects on
immune parameters have been hampered
because formulations and dosages vary
greatly, and routes of administration and
immunologic outcome measures have not
been standardized.
CDC investigators evaluated the effects
of isobutyl nitrite on the immune system
of BALB/c mice (38,39). The mice were
exposed to either 50 or 300 ppm isobutyl
nitrite for 6.5 hr/day, 5 days/week for up
to 18 weeks. Mice were sacrificed at vari-
ous times and antibody-producing cells
were enumerated; mitogenesis responses
were evaluated to PHA, Con A, PWM,
and lipopolysaccharide and skin test reac-
tions to purified protein derivative of
immunized mice were observed. No
immunotoxic effects were discerned,
although decreased thymic weights were
noted for female mice at the highest dose
levels (38,39).
Other investigators have noted decreases
in natural killer cell activity, helper
lymphocyte counts, and/or body weight in
mice exposed to nitrites. Lotzova et al.
(40) injected mice with 0.50 ml isobutyl
nitrite and noted significant depression of
natural killer cell activity in female
C57BL/6 x DBA/2 mice. Administration
of isobutyl nitrite by inhalation (2- to 3-
min exposures twice daily) also suppressed
natural killer cell function in mice (40).
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Ortiz and Rivera (41) exposed CD-I mice
to increasing amounts of amyl nitrite by
nasal administration for up to 21 weeks.
The total T-cell and suppressor cell counts
did not differ from mice exposed to saline
solutions. However, helper cell counts,
body weight, and weight gain rates were
significantly decreased in nitrite-exposed
versus control mice (41). Soderberg and
Barnett (42) exposed female C57BL/6N
mice to 900 ppm isobutyl nitrite by inhala-
tion chamber for 45 min per day for 14
days. Body weight was reduced 4%,
mixed-lymphocyte reaction (MLR) was
reduced 50-60%, and mitogen response to
ConAwas reduced was reduced 33% (42).
Although much laboratory work has
been done to evaluate nitrites and the
immune system, it remains unclear
whether continued nitrite use by HIV-
infected or uninfected individuals is
immunotoxic.
Nitrites andAIDS-related Kaposi's
Sarcoma. The epidemiology of Kaposi's
sarcoma (KS), the most commonly report-
ed cancer among AIDS patients, differs
markedly from the other opportunistic dis-
eases that have characterized the AIDS epi-
demic. KS has occurred much more fre-
quently among gay men with AIDS and
much less frequently among other AIDS
patients. Furthermore, the rate of increase
in KS cases has been lower than that of
other AIDS indicator diseases (43-46). KS
was almost never seen in HIV-infected
blood-transfusion recipients, even when
the presumed HIV donor developed KS
(47,48). KS was reported about twice as
often among white gay men with AIDS
than among black gay men with AIDS,
suggesting an association with increased
socioeconomic status or some other factor
(49). Women linked sexually to gay men
were reported with AIDS-related KS more
often than women infected with HIV by
heterosexual contact with intravenous drug
users (50). Wide geographic variations of
KS rates were reported among gay men
with AIDS in the United States (50).
These observations suggested that some
cofactor highly associated with gay lifestyle
was operating in conjunction with HIV in
the pathogenesis of AIDS-related KS.
Nitrite inhalants were suggested as one
possible factor (10,11,51-56).
There are several reasons to consider
nitrite inhalants as a KS cofactor. First, the
epidemiology of nitrite use in the United
States parallels that of HIV-related KS.
Nitrite inhalants are used more commonly
by gay men than others (6); use has been
declining since AIDS was first reported
(30) and has roughly paralleled the pattern
of reported KS cases, and use among
whites is greater than among blacks, as is
the incidence of KS (22). Second, some,
but not all, epidemiologic studies have
shown a statistical association between the
development of KS among gay men with
AIDS and the use of large quantities of
nitrite inhalants when compared with gay
men with AIDS, but without KS
(11,51-56). Third, anecdotal reports of
increased frequency ofAIDS-related KS on
the chest and face, especially the nose, and
in the lungs are consistent with the body
areas most heavily exposed to nitrite vapors
when inhaled. Finally, plausible mecha-
nisms of action have been proposed for
nitrites and their metabolites, such as cho-
lesteryl nitrite and nitrosamines, to be car-
cinogenic, and mutagenesis has been
demonstrated in the Ames test (7,57,58).
Nitrites are known to affect small blood
vessels, the anatomic site presumed to give
rise to KS (12).
Nitrite inhalants are one ofseveral fac-
tors proposed as KS promoters in HIV-
infected individuals. Other KS cofactors
proposed include a second sexually trans-
mitted agent and/or genetic factors
(48,59465).
Conclusions
In summary, nitrite inhalants are common-
ly abused substances in the United States.
Nitrite inhalants are associated with behav-
ioral relapse and HIV transmission among
gay men, with decreased lymphocyte
counts and natural killer cell activity in a
few laboratory studies, and they remain a
candidate cofactor in the pathogenesis of
AIDS-related KS.
Encouraging the decline in nitrite
abuse appears to be a worthwhile public
health goal. The most effective ways to
accomplish this goal are not clear. In the
United States, laws banning nitrite manu-
facture and sale were enacted in 1988 and
1990. However, use of nitrite inhalants
had started to decrease even before the laws
were implemented. What impact did dis-
cussions of scientific findings suggesting a
link between nitrites and AIDS, particular-
ly as reported in the predominantly gay
press, have on nitrite sales and use? What
impact did grass-roots organizations dis-
couraging nitrite use have? What alterna-
tive drugs of abuse will take the place of
nitrites bythose who discontinue use?
The search for cofactors in AIDS-relat-
ed KS remains an important scientific chal-
lenge. If the KS cofactor(s) can be identi-
fied, it mayprovide important insights into
the pathogenesis of AIDS and possibly
some forms ofcancer. Nitrite use is consis-
tent with much of the epidemiology of
AIDS-related KS. Further studies ofnitrite
use and other potential cofactors among
gay men with KS as well as women and
others with KS should be encouraged.
Animal models exposed to retroviruses and
nitrite inhalants should be pursued.
The possible links of nitrites with
AIDS and the other known adverse effects
of these inhaled substances suggest that
more attention to these products by clini-
cians and researchers is warranted.
Clinicians and community leaders should
discourage the use of nitrite inhalants.
Researchers should study further the asso-
ciations between nitrite use and HIV infec-
tion andAIDS.
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